Visual impairment

EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

Retrieved on: 
Martedì, Maggio 7, 2024
Optical coherence tomography, Șaeș, Patient, Retinitis pigmentosa, Safety, Research, PDE6B, Paratriathlon, Chorioretinitis, Visual impairment, Natural history, Disease, OCT, Snellen, Eye, GVF, ARVO, Visual acuity, Ageing, Pharmaceutical industry

These data were reported during an oral presentation* on May 6, at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, WA, US.

Key Points: 
  • These data were reported during an oral presentation* on May 6, at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, WA, US.
  • The positive 24-month follow-up data presented confirm results from the previous interim analysis of the trial conducted at the 12-month follow-up point and support preparation for a registrational trial for HORA-PDE6b in PDE6b RP patients.
  • Further discussions with health authorities in the US and Europe are planned to define the optimal path to making HORA-PDE6b available to PDE6b RP patients.
  • The treatment was administered in the more affected eye while the other eye served as an untreated control.

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Retrieved on: 
Lunedì, Maggio 6, 2024
Biotechnology, Health, General Health, Pharmaceutical, Optical, Health Technology, Other Science, Research, Genetics, Science, Clinical Trials, AMD, Patient, Cell, MM2, Geographic atrophy, MD, Doctor of Philosophy, OCT, Lineage, Paratriathlon, Degenerative disease, RPE, Atrophy, Therapy, Visual impairment, ELM

The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .

Key Points: 
  • The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells currently in development for the treatment of GA secondary to AMD.
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

Leading Experts Examine Patient-Centered Health Care Across the Lifespan at National Health Council Science of Patient Engagement Symposium

Retrieved on: 
Mercoledì, Maggio 8, 2024
Science, FDA, Ageism, Patient, Woman, Pediatrics, NHC, Symposium, Doctor of Philosophy, Research, Artificial intelligence, Adolescence, Survivor, FAAFP, Principal, MPH, Press club, Caregiver, Diagnosis, Visual impairment, Food and Drug Administration, National Health Council, Nursing

WASHINGTON, May 8, 2024 /PRNewswire/ -- Leading health care experts asked health care providers and policymakers to keep patients of all ages at the center of their decision-making process during the National Health Council (NHC) 2024 Science of Patient Engagement Symposium. The conference, entitled, Patient Experiences through their Lifespan, held May 8-9 at the National Press Club, brings together more than 180 policymakers, researchers, patients and patient advocates, and health care providers.

Key Points: 
  • The conference, entitled, Patient Experiences through their Lifespan , held May 8-9 at the National Press Club, brings together more than 180 policymakers, researchers, patients and patient advocates, and health care providers.
  • The Science of Patient Engagement Symposium explores standards and best practices that ensure every patient has legitimate input in their own medical care and that patient research results are applied equally to all individuals.
  • Today's Symposium also explores meaningful patient engagement, defined as patients who are recognized as equal partners and integrated in the development phases of science, research, and drug regulation.
  • The Science of Patient Engagement Symposium is an annual event where research leaders convene to share their experiences, accomplishments, best practices, and resulting translational impacts on the science of patient engagement.

Students Innovate to Improve Access to Urban Green Space

Retrieved on: 
Martedì, Maggio 7, 2024
Relaxation, Recreation, Disability, City, OTIS, Glasses, Mentorship, Visual impairment, STEM, Smartphone, Social, ESG, Student, Nursing

FARMINGTON, Conn., May 7, 2024 /PRNewswire/ -- Four student teams from around the world are regional winners in Otis' Made to Move Communities student challenge. In the fourth annual competition, students developed innovative mobility solutions aimed at expanding access to green space in urban communities to advance residents' wellbeing. Otis (NYSE: OTIS) is the world's leading elevator and escalator manufacturing, installation and service company.

Key Points: 
  • In the fourth annual competition, students developed innovative mobility solutions aimed at expanding access to green space in urban communities to advance residents' wellbeing.
  • The global student challenge for 2023-24 included more than 240 students across 15 countries and territories.
  • Developed a concept for a smart, green elevator that would include visual, tactile, auditory and olfactory elements often found in outdoor spaces, bringing a "virtual" green space to those with limited access to such spaces.
  • Prototyped a smart cane designed to give sensory feedback to individuals with visual impairment to improve navigation of green spaces.

Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C.

Retrieved on: 
Martedì, Maggio 7, 2024
Public, Summit, Partner, Risk, Policy, Disability, Advocacy, Kyowa Kirin, Spark Therapeutics, Biotechnology Innovation Organization, Human, BIO, Communication, Public policy, Novartis, Patient, MPH, Patient advocacy, Conditional sentence, Madison Hotel, Visual impairment, CVC, Knowledge, Mallinckrodt, Nursing

CHICAGO, May 7, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, will be hosting the ASPECT Patient Engagement and Advocacy Summit, May 14-16, 2024, at the Madison Hotel in Washington, D.C. The Summit will bring together ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program graduates (eye health patients and their allies), and program sponsors.

Key Points: 
  • Three-day event brings together patients, care partners, and public health champions to advance the goals of the Prevent Blindness ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program
    CHICAGO, May 7, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, will be hosting the ASPECT Patient Engagement and Advocacy Summit, May 14-16, 2024, at the Madison Hotel in Washington, D.C.
  • The Summit will bring together ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program graduates (eye health patients and their allies), and program sponsors.
  • The ASPECT Patient Engagement and Advocacy Summit is generously supported by Sustaining Level Partners Amgen, Genentech, and Novartis.
  • For information on Prevent Blindness advocacy efforts, please visit Advocacy.PreventBlindness.org , or contact Sara Brown, Director of Government Affairs, at [email protected] .

Carrie Naylor Promoted to Office Manager at United Real Estate Strive 212: Setting New Standards

Retrieved on: 
Giovedì, Maggio 2, 2024
Caffeine, National Association of Realtors, Perseverance, Office, Mentorship, Visual impairment, Paratriathlon, Real estate agent, Philosophy, Growth

WYOMISSING, Pa., May 2, 2024 /PRNewswire-PRWeb/ -- Carrie Naylor, Office Administrator for United Real Estate Strive 212 has recently been promoted to Office Manager. This achievement comes after working 5 dedicated years with the brokerage as an Administrator despite being visually impaired. Carrie's consistent commitment to the team of Realtors she works with is recognized by Owners Jennifer Dinatally, Realtor, and Frank Ramos, Broker/Owner, as they testified to her consistent contributions to brokerage Realtors by providing the support, reminders, and caffeine they need to build their businesses. "Frank and I could not be more grateful for all of Carrie's hard work and dedication over the years. She has truly been an integral part of our team's growth and success. We are excited to see how we grow together going forward!" Dinatally said.

Key Points: 
  • WYOMISSING, Pa., May 2, 2024 /PRNewswire-PRWeb/ -- Carrie Naylor, Office Administrator for United Real Estate Strive 212 has recently been promoted to Office Manager.
  • This achievement comes after working 5 dedicated years with the brokerage as an Administrator despite being visually impaired.
  • Upon assuming the role of Office Manager, Carrie Naylor expressed profound excitement and gratitude for the opportunity to elevate her career to new heights.
  • "As I welcome this new chapter as Office Manager at United Real Estate Strive 212, I am overwhelmed with gratitude for the unwavering support of my colleagues, mentors, and the entire United Real Estate Strive 212 family.

Prevent Blindness Announces Recipients of the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health, and the Rising Visionary Award

Retrieved on: 
Lunedì, Aprile 29, 2024
Education, Public, AOP, Religion, Achievement Medal, Health equity, Public health, Woman, Essay, School, Premature, All but dissertation, Mentorship, Empowerment, Doctor of Philosophy, Visual impairment, Life, OD, University college, Primary health care, Retinopathy, Culture, Psychology, Patient, Nursing, DPA, Retinoblastoma

CHICAGO, April 29, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety organization, has announced the recipient of the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health as Mission for Vision (MFV). Erica Shelton, OD, MS, FAAO, Clinical Instructor and PhD Candidate, The Ohio State University College of Optometry, has been named as the recipient of the fifth annual "Rising Visionary Award." Both award recipients will present at the 13th Annual Prevent Blindness Focus on Eye Health Summit, to be held as a virtual interactive event on July 10-11, 2024.

Key Points: 
  • "Prevent Blindness congratulates Mission for Vision and Dr. Erica Shelton as recipients of two of our most prestigious awards," said Jeff Todd, president and CEO of Prevent Blindness.
  • These award recipients were chosen by a volunteer selection committee, consisting of leading professionals in ophthalmology, optometry, advocacy, public health, and scientific communities.
  • The award serves as a living memorial to Jenny Pomeroy, who served as the CEO of Prevent Blindness Georgia from 1996 until 2013 and was a tireless champion of public health and vision advocacy.
  • For more information on the Prevent Blindness Jenny Pomeroy Award for Excellence in Vision and Public Health and the Rising Visionary Award, please visit PreventBlindness.org .

EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)

Retrieved on: 
Venerdì, Maggio 3, 2024
AMD, Blood, Risk, Commercial, Swissmedic, Ranibizumab, Teva, Paratriathlon, Partnership, Health Canada, Visual impairment, Growth, Retina, Patient, Macular degeneration, Marketing, CBO, Quality of life, VEGF, NAMD, Pharmaceutical industry

Press release // April 11, 2024

Key Points: 
  • Press release // April 11, 2024
    Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide
    Munich, Germany – Formycon AG (FSE: FYB) and Bioeq AG announce the commercial launch of FYB201, a biosimilar to Lucentis®1(Ranibizumab), in Canada and Switzerland.
  • The launch follows the marketing authorization granted by Health Canada under the trademark RanoptoTM2and Swissmedic under the trademark Ranivisio®3.
  • FYB201 was developed by Bioeq AG, a joint venture between Formycon AG and Polpharma Biologics Group BV.
  • In Canada and Switzerland, FYB201 has been approved for the treatment of age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.

2024 Helen Keller Achievement Awards Ceremony Celebrates Media Inclusion

Retrieved on: 
Venerdì, Aprile 19, 2024
AC3, Education, American Council, Radio, Glass, Disability, Perseverance, World War II, Talkington, Helen Keller, Lucasfilm, Netflix, Light, Perception, Visual impairment, Solomon R. Guggenheim, Journal, Organization, Film industry

LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) -- The American Foundation for the Blind (AFB) celebrated this evening the achievements of those champions for inclusion in media and the arts during its annual Helen Keller Achievement Awards held at the Japanese American National Museum in downtown Los Angeles.

Key Points: 
  • LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) -- The American Foundation for the Blind (AFB) celebrated this evening the achievements of those champions for inclusion in media and the arts during its annual Helen Keller Achievement Awards held at the Japanese American National Museum in downtown Los Angeles.
  • The evening’s honorees — filmmaker Shawn Levy, actor and advocate Marilee Talkington, and Lucasfilm Ltd. — were recognized for their steadfast commitment to keeping Helen Keller’s spirit alive as they drive inclusion in media for people with disabilities.
  • Since 1994, the Helen Keller Achievement Award has recognized the finest thought leaders, change-makers, and performing artists committed to carrying on Keller's mission to create a world of full and equal inclusion for people with disabilities.
  • For over 40 years, Helen Keller was AFB's leading ambassador, inspiring millions worldwide as she demonstrated all that can be accomplished through determination and perseverance.

Change in Leadership at AFB’s Journal of Visual Impairment & Blindness as Longtime Editor in Chief Sandra Lewis Steps Down, Robert Wall Emerson of Western Michigan University to Fill the Role

Retrieved on: 
Mercoledì, Aprile 17, 2024
ECC, Education, Research, Marilyn, Florida State University, Visual impairment, Life, Communication studies, Mathematics, Special education, Journal, Paratriathlon, Learning, Uncertainty, Literacy, Jimmy Buffett, Literature, FSU, Otorhinolaryngology, Dog, Orientation, San Francisco State University, Editorial, Deafblindness, Distinguished Service Award, Retirement, AER, Student, Division, Specialization, Acoustics, University, Textbook, Blind, Exceptional Children, Vanderbilt University, Rehabilitation, COMS, Curriculum, Management

Robert Wall Emerson, Ph.D., Western Michigan University, the journal’s research editor since 2012, will step into the role in July 2024.

Key Points: 
  • Robert Wall Emerson, Ph.D., Western Michigan University, the journal’s research editor since 2012, will step into the role in July 2024.
  • Despite her busy schedule, Dr. Lewis graciously accepted the role of editor-in-chief of JVIB in 2015.
  • In 2004, he moved to Western Michigan University, where he currently works as a professor in the Department of Blindness and Low Vision Studies.
  • Taken together with his vast areas of expertise, Dr. Wall Emerson is the natural choice to succeed Dr. Lewis as editor in chief of the journal.